Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | CBX7 | O95931 | 2/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.35 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205319 | 0.85 | PGR (0.43) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL11959112 | 0.82 | CASP6 (0.43) | IDO1MEN1KMT2AGAA | |
| SCHEMBL2482415 | 0.80 | PGR (0.41) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL11979737 | 0.80 | IDO1 (0.50) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL16377143 | 0.77 | IDO1 (0.62) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL12205346 | 0.73 | IDO1 (0.43) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL10826731 | 0.70 | IDO1 (0.50) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL2485622 | 0.69 | IDO1 (0.41) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL11959125 | 0.69 | IDO1 (0.41) | IDO1CBX7CDYLCDYL2CDY1; CDY1B | |
| SCHEMBL2480466 | 0.68 | IDO1 (0.42) | IDO1CBX7CDYLCDYL2CDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1891075-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125784-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | RORB, NR3C2, NR1H2 | IDO1 1371/4885CBX7 2072/4885CDYL 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.